Target intelligence / Profile preview

Proline racemase (null)

Target
null
Molecular classification
Enzyme, Amino acid racemase, Pyridoxal phosphate-independent racemase
01

Overview

Proline racemase is an enzyme that catalyzes the interconversion of L-proline and D-proline. It is found in bacteria and certain protozoan parasites, like Trypanosoma cruzi, but is absent in mammals. The enzyme functions via a pyridoxal phosphate-independent, two-base mechanism, involving two active-site cysteine residues that operate as general acids/bases. In T. cruzi, the secreted form of proline racemase acts as a B-cell mitogen and plays a role in immune evasion during Chagas disease. Structurally, it is a homodimer, with each monomer hosting an active-site capable of catalysis. Transition state analogues, particularly pyrrole-2-carboxylic acid, inhibit the enzyme by mimicking the substrate’s transition state, binding to the catalytic center and blocking function. The absence of proline racemase in mammals and its essential role in pathogenic organisms make it an attractive target for selective drug development.

Other names
Proline amino acid racemasePRACL-proline racemaseD-proline racemase
02

Mechanism of action

Inhibitors block enzyme-mediated racemization of proline by covalently or non-covalently interfering with active-site cysteine residues, preventing conversion of L- to D-proline or vice versa

03

Biological functions

Catalysis of interconversion between L-proline and D-prolineRegulation of proline metabolism in bacteriaB-cell mitogen in certain parasitic protozoa (Trypanosoma cruzi)
04

Disease associations

Infection (e.g., Chagas disease, a role in immune evasion by Trypanosoma cruzi)Other (potential antibacterial drug target due to absence in mammalian hosts and role in pathogen viability)
05

Safety considerations

Target absent in mammalian host, therefore selectivity and low host toxicity are likely, but off-target effects of small-molecule inhibitors may still occurImmune-modulatory effects via B-cell activation by T. cruzi enzyme may complicate host response
06

Interacting drugs

Pyrrole-2-carboxylic acid (P2C, a competitive inhibitor and transition state analogue)

1 more in the full profile.

07

Biomarkers

Presence of proline racemase gene/protein in pathogens (e.g., Trypanosoma cruzi) may serve as a diagnostic or pharmacodynamic biomarker, but not established in clinical useNo validated human efficacy biomarkers

Beyond the preview

Go deeper on Proline racemase (null).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Proline racemase (null).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call